Abaloparatide

Abaloparatide is a synthetic 34-amino acid analog of parathyroid hormone-related protein (PTHrP 1-34), FDA-approved in 2017 for postmenopausal osteoporosis. It selectively binds the RG conformation of the PTH1R receptor, producing potent anabolic bone formation with lower hypercalcemia incidence than teriparatide.

Abaloparatide is a synthetic 34-amino acid peptide analog of human parathyroid hormone-related protein (PTHrP 1-34). Marketed as Tymlos (Radius Health), it was FDA-approved in 2017 for the treatment of postmenopausal women with osteoporosis at high fracture risk.

Overview

Abaloparatide emerged from the understanding that PTH and PTHrP, despite sharing the PTH1R receptor, produce different signaling kinetics and biological outcomes. PTHrP produces more transient receptor activation than PTH, and this transience favors bone formation over resorption. Abaloparatide was engineered to optimize this selectivity by preferentially binding the RG (guanine nucleotide-sensitive, signaling-competent) conformation of PTH1R, rather than the R0 (guanine nucleotide-insensitive, internalization-favoring) conformation that PTH also engages.

The clinical result is an anabolic bone agent that rivals or exceeds teriparatide in BMD gains at certain sites while producing significantly less hypercalcemia — a meaningful advantage for patient tolerability and safety monitoring. Abaloparatide joins teriparatide and romosozumab as the three available anabolic bone agents, expanding the therapeutic armamentarium for severe osteoporosis.

Mechanism of Action

Selective PTH1R Binding (RG Conformation)

PTH1R exists in two conformational states:

  1. RG conformation: G protein-coupled, signaling-competent state. Ligand binding to RG triggers cAMP production and downstream osteoblast activation, with rapid dissociation and transient signaling.
  2. R0 conformation: G protein-uncoupled state. Ligand binding to R0 produces prolonged receptor occupancy, sustained cAMP signaling, and receptor internalization.

Abaloparatide binds RG with high affinity but has lower affinity for R0 compared to PTH 1-34. This RG selectivity produces:

  • Transient cAMP response: Brief, potent osteoblast activation followed by rapid signal termination.
  • Less sustained signaling: Reduced prolonged cAMP elevation, which is associated with bone resorption and hypercalcemia.
  • Favorable formation/resorption ratio: The transient signaling profile preferentially stimulates bone formation over resorption (Hattersley et al., 2016).

Downstream Bone Formation Pathways

Like teriparatide, abaloparatide activates osteoblast formation through:

  • cAMP/PKA/CREB signaling: Drives osteoblast differentiation gene transcription.
  • Wnt pathway activation: Suppresses sclerostin, activating canonical Wnt signaling.
  • Osteoblast survival: Anti-apoptotic effects on osteoblasts and osteocytes.
  • Modeling-based formation: Evidence suggests abaloparatide may stimulate more modeling-based (adding bone to surfaces without prior resorption) versus remodeling-based formation compared to teriparatide, though this remains under investigation (Bahar et al., 2016).

Comparison of Receptor Pharmacology

PropertyPTH 1-34PTHrP 1-36Abaloparatide
RG binding affinityHighHighHigh
R0 binding affinityHighLowLow
cAMP response durationProlongedTransientTransient
Hypercalcemia potentialModerateLowLow
Bone formation potencyHighHighHigh

Reconstitution Calculator

Reconstitution Calculator

Calculate your peptide dosing

Draw Volume
0.100mL
Syringe Units
10units
Concentration
2,500mcg/mL
Doses / Vial
20doses
Vial Total
5mg
Waste / Vial
0mcg
Syringe Cap.
100units · 1mL
How to reconstitute
Gather & prepare
1/6Gather & prepare

Set up a clean workspace with all supplies ready.

1.Wash hands thoroughly, put on disposable gloves
2.Your 5mg peptide vial (lyophilized powder)
3.Bacteriostatic water (you'll need 2mL)
4.A 3–5mL syringe with 21–25 gauge needle for reconstitution
5.Alcohol swabs (70% isopropyl)
Use bacteriostatic water (0.9% benzyl alcohol) for multi-dose vials. Sterile water is only safe for single-use.
Supply Planner

7x / week for weeks

·
40%
2vials
28 doses20 days/vial12 leftover
Cost Breakdown
Vial price
$0.00per dose
$0.00 /week$0 /month
Store 2-8°C30 day shelf lifeSwirl gentlyFor research purposes only

Research

Head-to-Head with Teriparatide

The ACTIVE trial provided the first direct comparison of abaloparatide and teriparatide within a single randomized trial:

Outcome (18 months)AbaloparatideTeriparatidePlacebo
Spine BMD change+11.2%+8.6%+0.6%
Total hip BMD change+4.2%+2.6%-0.1%
Femoral neck BMD change+3.6%+2.2%-0.4%
Vertebral fracture RR-86%-80%
Hypercalcemia incidence3.4%6.4%0.4%

The greater BMD gains at hip sites are particularly notable, as hip fractures carry the highest morbidity and mortality among osteoporotic fractures. However, the trial was not powered for direct statistical comparison of fracture outcomes between the two active treatments.

BMD Response Kinetics

Abaloparatide produces notably rapid BMD gains in the first 6 months of therapy:

  • Lumbar spine: ~7% at 6 months, reaching ~11% at 18 months
  • Total hip: ~3% at 6 months, reaching ~4% at 18 months
  • Clinical significance: The rapid early response may translate to earlier fracture risk reduction, particularly important for patients at imminent fracture risk

Bone turnover markers show a characteristic pattern:

  • P1NP (formation): Rapid early increase, peaking at ~1 month, then gradually declining
  • CTX (resorption): More gradual increase, smaller magnitude than P1NP
  • Net effect: The formation-resorption differential (anabolic window) is more pronounced and earlier with abaloparatide than with teriparatide

ACTIVExtend Follow-up

The ACTIVExtend trial continued ACTIVE participants into a 24-month open-label alendronate extension phase. Patients who had received abaloparatide followed by alendronate showed:

  • Sustained fracture protection: 84% relative risk reduction in new vertebral fractures over the combined 43-month period (18 months abaloparatide + 24 months alendronate) compared to 24 months alendronate alone.
  • Continued BMD gains: Additional lumbar spine BMD increases of ~3% during the alendronate phase, building on prior abaloparatide gains. Total hip BMD was maintained or slightly increased.
  • Non-vertebral fracture reduction: 39% over the combined period.

This trial was instrumental in establishing the anabolic-to-antiresorptive sequential therapy paradigm (Cosman et al., 2019).

Transdermal Patch Development (ABTS)

A significant advancement in development is the abaloparatide-patch (abaloparatide-sBCTP), a wearable solid microstructured transdermal system (sMTS):

  • Technology: Microneedle patch applied to the abdomen for ~5 minutes, delivering abaloparatide through the skin.
  • Phase 2 results: The transdermal patch (300 mcg dose) produced BMD increases comparable to subcutaneous abaloparatide at the lumbar spine, with a favorable tolerability profile.
  • Phase 3 (wearABLe study): Ongoing evaluation of the patch system for ease of use and compliance advantages. If approved, it would be the first transdermal anabolic osteoporosis therapy, potentially improving adherence by eliminating injection burden.
  • Pharmacokinetics: The patch produces a slightly different PK profile (broader Tmax) than SC injection, but maintains the transient signaling pattern critical for bone anabolism (Cosman et al., 2020).

Cortical vs. Trabecular Bone Effects

A distinguishing feature of abaloparatide is its effect on cortical bone:

  • Both abaloparatide and teriparatide increase trabecular bone volume and connectivity.
  • Abaloparatide may produce more favorable cortical bone outcomes, with less cortical porosity increase during treatment compared to teriparatide.
  • HR-pQCT studies suggest abaloparatide increases cortical thickness and bone strength at the radius and tibia, sites that are predominantly cortical (Bilezikian et al., 2018).

ACTIVE Trial (Pivotal Phase 3)

The Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) was a 18-month randomized, double-blind, placebo- and active-controlled trial in 2,463 postmenopausal women with osteoporosis. Key results:

  • Vertebral fractures: Abaloparatide reduced new vertebral fractures by 86% vs. placebo (0.58% vs. 4.22%, p<0.001). Teriparatide reduced them by 80%.
  • Non-vertebral fractures: Abaloparatide reduced non-vertebral fractures by 43% vs. placebo (2.7% vs. 4.7%, p=0.049). Teriparatide did not reach significance vs. placebo in this trial.
  • Major osteoporotic fractures: Abaloparatide reduced these by 70% vs. placebo.
  • BMD gains (18 months): Lumbar spine +11.2% (abaloparatide) vs. +8.6% (teriparatide) vs. +0.6% (placebo). Total hip +4.2% vs. +2.6% vs. -0.1%. Femoral neck +3.6% vs. +2.2% vs. -0.4%.
  • Hypercalcemia: 3.4% with abaloparatide vs. 6.4% with teriparatide (significant difference) (Miller et al., 2016).

Safety Profile

Abaloparatide has a favorable safety profile established in the ACTIVE and ACTIVExtend trials:

  • Common adverse effects: Injection site reactions (redness 14%, edema 9%), dizziness (10%), nausea (8%), headache (8%), palpitations (2%).
  • Hypercalcemia: 3.4% incidence (vs. 6.4% with teriparatide in ACTIVE) — a significant clinical advantage. Serum calcium monitoring is still recommended.
  • Heart rate: Small transient increases (~5 bpm) observed post-injection, resolving within hours. No significant cardiovascular events.
  • Orthostatic hypotension: Reported in 4% of patients.
  • Antibody development: Low immunogenicity. Anti-abaloparatide antibodies developed in ~49% of patients but were non-neutralizing and had no effect on efficacy or safety.

Black Box Warning

Like teriparatide, abaloparatide carries a black box warning regarding osteosarcoma risk based on rat studies (dose-dependent osteosarcoma in Fischer 344 rats with long-duration, high-dose exposure). Treatment duration is limited to 2 years (cumulative lifetime exposure to anabolic bone agents). The same caveats apply regarding the poor translatability of the rat model to humans.

Contraindications

  • Patients at increased risk for osteosarcoma (Paget's disease, unexplained elevated alkaline phosphatase, open epiphyses, prior skeletal radiation)
  • Pre-existing hypercalcemia
  • Severe renal impairment (limited data)

Pharmacokinetic Profile

Abaloparatide — Pharmacokinetic Curve

Subcutaneous injection (80 mcg/day)
0%25%50%75%100%0m1h2h3h4h5hTimeConcentration (% peak)T_max 29mT_1/2 1h
Half-life: 1hT_max: 31mDuration shown: 5h

Quick Start

Typical Dose
80 mcg
Frequency
Once daily
Route
Subcutaneous injection (80 mcg/day)
Cycle Length
Up to 2 years (lifetime maximum)
Storage
Refrigerate pre-filled pen at 2-8°C, do not freeze. Discard after 30 days even if medication remains

Molecular Structure

2D Structure
Abaloparatide molecular structure
Molecular Properties
Formula
C174H300N56O49S2
Weight
3 Da
Length
34 amino acids
CAS
247062-33-5
PubChem CID
76943386
Exact Mass
3959.2738 Da
LogP
-20.9
TPSA
1740 Ų
H-Bond Donors
61
H-Bond Acceptors
60
Rotatable Bonds
145
Complexity
9310
Identifiers (SMILES, InChI)
InChI
InChI=1S/C174H300N56O49/c1-26-93(20)136(228-165(274)126(80-232)224-141(250)101(39-28-32-56-176)200-129(236)78-195-140(249)100(38-27-31-55-175)201-161(270)123(73-133(243)244)223-160(269)121(71-98-76-190-82-197-98)220-158(267)118(68-90(14)15)216-155(264)114(64-86(6)7)213-148(257)107(45-50-127(180)234)207-159(268)120(70-97-75-189-81-196-97)219-151(260)111(49-54-132(241)242)209-164(273)125(79-231)225-167(276)135(92(18)19)227-139(248)94(21)179)168(277)210-108(46-51-128(181)235)149(258)222-124(74-134(245)246)162(271)217-112(62-84(2)3)152(261)205-105(44-37-61-194-173(187)188)143(252)203-103(42-35-59-192-171(183)184)142(251)204-104(43-36-60-193-172(185)186)144(253)206-110(48-53-131(239)240)150(259)214-115(65-87(8)9)154(263)215-113(63-85(4)5)153(262)208-109(47-52-130(237)238)147(256)202-102(40-29-33-57-177)145(254)211-116(66-88(10)11)156(265)218-119(69-91(16)17)166(275)230-174(24,25)170(279)226-106(41-30-34-58-178)146(255)212-117(67-89(12)13)157(266)221-122(72-99-77-191-83-198-99)163(272)229-137(96(23)233)169(278)199-95(22)138(182)247/h75-77,81-96,100-126,135-137,231-233H,26-74,78-80,175-179H2,1-25H3,(H2,180,234)(H2,181,235)(H2,182,247)(H,189,196)(H,190,197)(H,191,198)(H,195,249)(H,199,278)(H,200,236)(H,201,270)(H,202,256)(H,203,252)(H,204,251)(H,205,261)(H,206,253)(H,207,268)(H,208,262)(H,209,273)(H,210,277)(H,211,254)(H,212,255)(H,213,257)(H,214,259)(H,215,263)(H,216,264)(H,217,271)(H,218,265)(H,219,260)(H,220,267)(H,221,266)(H,222,258)(H,223,269)(H,224,250)(H,225,276)(H,226,279)(H,227,248)(H,228,274)(H,229,272)(H,230,275)(H,237,238)(H,239,240)(H,241,242)(H,243,244)(H,245,246)(H4,183,184,192)(H4,185,186,193)(H4,187,188,194)/t93-,94-,95-,96+,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,135-,136-,137-/m0/s1
InChIKeyBVISQZFBLRSESR-XSCWXTNMSA-N

Research Indications

Osteoporosis (FDA-Approved)

Strong Evidence
Postmenopausal Osteoporosis

FDA-approved for postmenopausal women with osteoporosis at high risk for fracture or who have failed other therapies.

Strong Evidence
Male Osteoporosis

FDA-approved for men with osteoporosis at high risk for fracture or intolerant to other treatments.

Bone Health Research

Strong Evidence
Fracture Prevention

Phase III trials demonstrated substantial reduction in vertebral and nonvertebral fractures.

Good Evidence
Sequential Therapy

ACTIVExtend trial showed benefits of abaloparatide followed by alendronate for maintained bone protection.

Research Protocols

subcutaneous Injection

Abaloparatide is administered as a once-daily subcutaneous injection in the periumbilical (around the navel) region of the abdomen. It comes in pre-filled pen devices (Tymlos). Cumulative lifetime use is limited to 2 years due to theoretical osteosarcoma risk observed in rodent studies. A transdermal patch formulation is also in development.

GoalDoseFrequency
Osteoporosis treatment80 mcgOnce daily
Reconstitution Guide (mg vial + mL BAC water)
  1. Store pen refrigerated at 2-8°C (do not freeze)
  2. Allow to reach room temperature before injection
  3. Attach new needle for each injection
  4. Inject subcutaneously in periumbilical region
  5. Rotate injection sites
  6. Discard pen after 30 days even if medication remains

Interactions

Peptide Interactions

BPC-157compatible

Different mechanisms; no known interactions.

TB-500compatible

Different mechanisms; no known interactions.

Teriparatideavoid

Do not use concurrently; both are PTH receptor agonists. Choose one or use sequentially.

What to Expect

What to Expect

Month 1-3

Bone formation markers increase; initial BMD changes begin

Month 3-6

Significant BMD increases at spine, hip, and femur

Month 6-12

Continued bone density improvements; fracture risk reduction

Month 12-18

Maximum benefits in ACTIVE trial; substantial fracture reduction

Month 18-24

Transition to maintenance therapy (e.g., bisphosphonates) recommended

Safety Profile

Common Side Effects

  • Hypercalciuria (high calcium in urine)
  • Dizziness
  • Nausea
  • Headache
  • Palpitations
  • Fatigue
  • Upper abdominal pain
  • Vertigo
  • Injection site reactions

Contraindications

  • Paget's disease of bone
  • Prior external beam or implant radiation therapy to skeleton
  • Bone metastases or history of skeletal malignancies
  • Metabolic bone diseases other than osteoporosis
  • Pre-existing hypercalcemia
  • Pregnancy or nursing
  • Cumulative use exceeding 2 years lifetime

Discontinue If

  • Signs of hypercalcemia (confusion, fatigue, excessive thirst)
  • Persistent bone pain
  • Severe dizziness or fainting
  • Allergic reactions

Quality Indicators

What to look for

  • Clear, colorless solution
  • Pharmaceutical grade (Tymlos/Eladynos)
  • Proper cold chain maintained
  • Intact pen device
  • Within expiration date

Caution

  • Research-grade products lack FDA oversight
  • Temperature excursions may affect potency

Red flags

  • Cloudy or discolored solution
  • Particulates visible
  • Exposed to freezing or high temperatures
  • Damaged pen device

Frequently Asked Questions

References (12)

  1. [1]
    Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis (ACTIVE Trial) (2016)
  2. [3]
    Phase 2 Dose-finding Study of BA058 in Postmenopausal Women (2015)
  3. [6]
  4. [5]
  5. [10]
    Bilezikian JP et al Abaloparatide in the treatment of postmenopausal osteoporosis: efficacy and safety results from phase 2 and 3 clinical trials Curr Med Res Opin (2018)
  6. [11]
  7. [7]
  8. [12]
  9. [8]
  10. [9]
  11. [2]
  12. [4]
Updated 2026-03-08Sources: jabronistore-wiki, peptide-wiki-mdx, pubchem, peptide-wiki-mdx-v2

On this page